MIRM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Mirum Pharmaceuticals (MIRM) is a good buy for a beginner investor with a long-term horizon and $50,000-$100,000 available for investment. The company demonstrates strong revenue growth, positive analyst sentiment, and multiple upcoming catalysts that could significantly enhance its valuation. Despite short-term technical indicators showing mixed signals, the long-term growth potential outweighs these concerns.
The MACD is negative and expanding, suggesting bearish momentum in the short term. RSI is neutral at 33.751, indicating no clear overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading near a key support level of 92.313. Overall, the technicals are mixed but lean slightly positive for long-term investors.
Analysts have consistently raised price targets, with a consensus of strong growth potential and multiple catalysts in
The company is conducting four pivotal trials that could expand its market reach significantly.
The acquisition of Bluejay Therapeutics enhances its pipeline and could generate over $750 million in annual revenue.
Revenue from Livmarli indicates strong demand in the rare liver disease market.
Recent financials show a drop in net income (-75.91% YoY) and EPS (-77.55% YoY), which may concern some investors.
Short-term technical indicators like MACD and RSI do not show strong bullish momentum.
In Q4 2025, revenue increased by 49.81% YoY to $148.93 million, showcasing strong growth. However, net income dropped by 75.91% YoY to -$5.73 million, and EPS declined by 77.55% YoY to -0.11. Gross margin improved to 81.02%, up 5.10% YoY, indicating operational efficiency.
Analysts are overwhelmingly positive on MIRM, with multiple firms raising price targets to the $125-$132 range and maintaining Buy or Outperform ratings. Analysts highlight strong commercial momentum, durable growth in Livmarli, and potential catalysts from pivotal trials over the next 18 months.
